Stocks and Investing Stocks and Investing
Thu, December 12, 2024
[ 12:21 AM ] - Insider Monkey
Advanced Micro Devices (AMD) Hit by AI Chip Competition, BofA Downgrades Stock
[ 12:21 AM ] - The Motley Fool
Why Broadcom Stock Was Climbing Today
Wed, December 11, 2024
[ 10:41 PM ] - Seeking Alpha
Elevance Health: A Quality Underpriced Stock Returning To Health
[ 10:41 PM ] - Seeking Alpha
FactSet: Challenge Of Slowing Growth Amid A Stock Price Rise
[ 10:41 PM ] - Seeking Alpha
Investigation Into AMMO's Accounting Piles On Financial Weakness
[ 10:41 PM ] - Business Insider
A couple in their 30s who hit a seven-figure net .. ex funds explain why they shifted to ETFs in 2024
[ 10:22 PM ] - Associated Press
Stock market today: World stocks are mixed ahead of key US inflation data
[ 10:22 PM ] - Inside Bitcoins
Raydium Price Prediction: RAY Tops Gainers With 2 .. % Pump On Binance Listing News - Is SLAP Up Next?
[ 10:22 PM ] - Santa Rosa Press Democrat
Proposed merger of Kroger and Albertsons is halted by federal, state judges
[ 10:22 PM ] - FXStreet
Why is the ECB set to cut interest rates again and what does that mean
[ 10:22 PM ] - FXStreet
Forex Today: US CPI data and BoC rate decision to lift market volatility
[ 10:21 PM ] - Business Insider
Nasdaq soars above 20,000 for the first time as stocks jump on rate-cut bets
[ 10:21 PM ] - Bloomberg L.P.
Hermes Family in Talks to Invest in French Insurer Albingia
[ 10:21 PM ] - The Motley Fool
Prediction: SoFi Technologies Will Outperform the Market. Here's Why
[ 10:21 PM ] - Barron's
Where the Market Is Headed in 2025, From 4 Money Pros
[ 10:21 PM ] - Seeking Alpha
Invest In $95,000 BDC Portfolio For $10,000 Annual Income And Durable Compounding
[ 10:21 PM ] - Bloomberg L.P.
Nvidia, AMD and Intel Invest in Startup Bringing Light to Chips
[ 10:04 PM ] - Seeking Alpha
Nvidia: Earnings Fail To Impress Again
[ 10:04 PM ] - Seeking Alpha
Fortive Corporation: Undervaluation And Stability Give It An Edge (Rating Upgrade)
[ 10:04 PM ] - Business Insider
Sustainability-linked bond sales have tanked amid a shift in ESG sentiment
[ 10:03 PM ] - Insider Monkey
How Rezolve AI (RZLV) is Changing E-Commerce with AI and Conversational Apps
[ 10:03 PM ] - Seeking Alpha
Gold: I'd Love To Be Bullish, But Not At These Levels
[ 10:03 PM ] - Seeking Alpha
EQWL: A Low-Valuation Equal-Weight ETF, Outperforming Peers But Lagging The S&P 500 Index
[ 10:03 PM ] - Seeking Alpha
BE Semiconductor: A Market Leader With Enormous Dividend Growth Potential
[ 10:03 PM ] - Seeking Alpha
Verizon: Narrow Margin Of Safety Per Graham P/E And Number
[ 10:03 PM ] - Insider Monkey
Super Micro Computer (SMCI): Navigating AI Growth and Financial Scandals
[ 10:03 PM ] - Seeking Alpha
2 Great BDCs, Up To 10% Yield, For A Bright And Merry Christmas
[ 10:02 PM ] - Seeking Alpha
Oracle: The Market Has Given Us An Early Christmas Present (Rating Upgrade)
[ 10:02 PM ] - Seeking Alpha
Southwest Airlines Will Deliver Great News Into 2025 And Beyond
[ 10:02 PM ] - Seeking Alpha
Immunome: A Recently Acquired Lead Asset And A Small Market

Immunome: A Recently Acquired Lead Asset And A Small Market


Published on 2024-12-11 22:02:40 - Seeking Alpha
  Print publication without navigation

  • Immunome has a turbulent history, shifting focus from COVID-19 therapies to oncology. Read what the future may hold for this small-cap biotech. Learn more on IMNM stock here.

The article on Seeking Alpha discusses Immunome, Inc., a biopharmaceutical company focused on developing targeted cancer therapies. It highlights Immunome's recent acquisition of a lead asset, IM-1021, which is a novel antibody targeting the CD47/SIRPĪ± pathway, known for its potential in cancer immunotherapy. The acquisition was part of a broader strategy to bolster Immunome's pipeline with promising candidates. The article also touches on the company's market capitalization, which remains small, suggesting potential for growth but also inherent risks associated with early-stage biotech ventures. It discusses the implications of this acquisition for Immunome's future, including the potential to advance their clinical trials and the competitive landscape in cancer immunotherapy. The piece concludes by analyzing the investment perspective, noting the speculative nature of investing in such companies due to the high risk and high reward potential in the biotech sector.

Read the Full Seeking Alpha Article at:
[ https://seekingalpha.com/article/4743627-immunome-a-recently-acquired-lead-asset-and-a-small-market ]
Contributing Sources